JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal

  • J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.